Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 24,065	$ 21,304
Prepaid expenses and other current assets	824	1,118
Total current assets	24,889	22,422
Long-term assets
Property and equipment, net	28	33
Operating lease right-of-use assets	279	421
Intangible assets, net	11,665	12,637
Other long-term assets		40
Total assets	36,861	35,553
Current liabilities
Accounts payable	2,406	3,254
Accrued compensation	932	728
Accrued clinical trial site costs	3,156	3,420
Operating lease liabilities	337	282
Other current liabilities	415	323
Total current liabilities	7,246	8,007
Long-term liabilities
Contingent liability for Essentialis purchase price	9,305	9,547
Long-term lease liabilities		175
Total liabilities	16,553	17,760
Commitments and contingencies (Note 6)
Stockholders’ equity
Common stock, $0.001 par value, 250,000,000 shares authorized, 120,088,816 and 79,864,310 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively.	120	80
Additional paid-in-capital	245,993	231,068
Accumulated deficit	(225,804)	(213,355)
Accumulated other comprehensive loss	(1)
Total stockholders’ equity	20,308	17,793
Total liabilities and stockholders’ equity	36,861	35,553
2018 PIPE Warrant Liability [Member]
Long-term liabilities
Warrant liability	$ 2	$ 31